NASDAQ:EXAS - EXACT Sciences Stock Price, News, & Analysis

EXACT Sciences trades on the NASDAQ under the ticker symbol "EXAS."

EXACT Sciences Co. (NASDAQ:EXAS) issued its quarterly earnings results on Tuesday, October, 30th. The medical research company reported ($0.37) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.42) by $0.05. The medical research company earned $118.29 million during the quarter, compared to the consensus estimate of $109.33 million. EXACT Sciences had a negative return on equity of 20.18% and a negative net margin of 35.83%. The business's quarterly revenue was up 63.0% on a year-over-year basis. During the same period in the previous year, the business earned ($0.23) EPS. View EXACT Sciences' Earnings History.

EXACT Sciences is scheduled to release their next quarterly earnings announcement on Thursday, February 21st 2019. View Earnings Estimates for EXACT Sciences.

EXACT Sciences will be holding an earnings conference call on Thursday, February 21st at 5:00 PM Eastern. Interested parties can register for or listen to the call using this link or dial in at 8772010168.

EXACT Sciences issued an update on its FY 2018 earnings guidance on Monday, January, 7th. The company provided EPS guidance of for the period. The company issued revenue guidance of $454-455 million, compared to the consensus revenue estimate of $438.39 million.EXACT Sciences also updated its Q4 2018 guidance to EPS.

12 brokerages have issued twelve-month target prices for EXACT Sciences' shares. Their predictions range from $74.00 to $109.00. On average, they anticipate EXACT Sciences' stock price to reach $89.90 in the next year. This suggests a possible upside of 1.5% from the stock's current price. View Analyst Price Targets for EXACT Sciences.

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for EXACT Sciences in the last year. There are currently 2 hold ratings and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for EXACT Sciences.

Media stories about EXAS stock have been trending neutral on Saturday, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. EXACT Sciences earned a media sentiment score of 0.2 on InfoTrie's scale. They also gave headlines about the medical research company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the stock's share price in the next few days.

Some companies that are related to EXACT Sciences include Iqvia (IQV), Incyte (INCY), Icon (ICLR), PRA Health Sciences (PRAH), Charles River Laboratories Intl. (CRL), Exelixis (EXEL), Syneos Health (SYNH), BTG (BTGGF), Medpace (MEDP), Intrexon (XON), Eloxx Pharmaceuticals (ELOX), Sorrento Therapeutics (SRNE), STARPHARMA HOLD/S (SPHRY), Pieris Pharmaceuticals (PIRS) and Anavex Life Sciences (AVXL).

EXACT Sciences' stock is owned by a number of of institutional and retail investors. Top institutional investors include Frontier Capital Management Co. LLC (1.00%), Geode Capital Management LLC (0.97%), Jennison Associates LLC (0.85%), Eagle Asset Management Inc. (0.81%), CIBC Private Wealth Group LLC (0.74%) and Baillie Gifford & Co. (0.72%). Company insiders that own EXACT Sciences stock include D Scott Coward, Graham Peter Lidgard, Jeffrey Thomas Elliott, Katherine S Zanotti, Kevin T Conroy, Maneesh Arora, Michael S Wyzga and Thomas D Carey. View Institutional Ownership Trends for EXACT Sciences.

EXAS stock was sold by a variety of institutional investors in the last quarter, including GABELLI & Co INVESTMENT ADVISERS INC., Frontier Capital Management Co. LLC, KAMES CAPITAL plc, Eagle Asset Management Inc., Victory Capital Management Inc., CIBC Private Wealth Group LLC, Macquarie Group Ltd. and Kornitzer Capital Management Inc. KS. Company insiders that have sold EXACT Sciences company stock in the last year include D Scott Coward, Graham Peter Lidgard, Jeffrey Thomas Elliott, Katherine S Zanotti, Kevin T Conroy, Maneesh Arora, Michael S Wyzga and Thomas D Carey. View Insider Buying and Selling for EXACT Sciences.

EXAS stock was acquired by a variety of institutional investors in the last quarter, including Eaton Vance Management, First Trust Advisors LP, Intrinsic Edge Capital Management LLC, Geode Capital Management LLC, R.H. Dinel Investment Counsel Inc., Foresters Investment Management Company Inc., Columbus Circle Investors and Wisconsin Capital Management LLC. View Insider Buying and Selling for EXACT Sciences.

Shares of EXAS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of EXAS stock can currently be purchased for approximately $88.55.

EXACT Sciences has a market capitalization of $10.88 billion and generates $265.99 million in revenue each year. The medical research company earns $-114,390,000.00 in net income (profit) each year or ($0.99) on an earnings per share basis. EXACT Sciences employs 1,268 workers across the globe.

The official website for EXACT Sciences is http://www.exactsciences.com.

EXACT Sciences' mailing address is 441 CHARMANY DRIVE, MADISON WI, 53719. The medical research company can be reached via phone at 608-284-5700.